Adult; Belgium/epidemiology; Body Mass Index; Body Weight; Cholesterol/blood; Cholesterol, HDL/blood; Cohort Studies; Comorbidity; Female; Fibrinogen/analysis; Follow-Up Studies; Gastroplasty; Humans; Hyperglycemia/epidemiology; Hyperinsulinism/epidemiology; Hypertriglyceridemia/epidemiology; Insulin/blood; Insulin Resistance; Male; Obesity, Morbid/blood/physiopathology/surgery; Prevalence; Severity of Illness Index; Triglycerides/blood; Uric Acid/blood; Weight Loss
Abstract :
[en] Obesity is a prevalent metabolic disorder associated with high morbidity and mortality rates. Medical treatment rarely succeeds, and bariatric surgery has been proposed as an alternative therapy. The purpose of this non-controlled retrospective study was to evaluate time-course changes in body weight in severely obese patients who underwent vertical ring gastroplasty or adjustable silicone gastric banding, and to assess the prevalence and potential reversibility of several of the biological abnormalities associated with morbid obesity. From an initial cohort comprising 658 patients, regular body weight measurements and biological data were obtained in 505 patients [419 females, 86 males; age 36 +/- 11 years; body mass index 42.7 +/- 6.9 kg/m2; (mean +/- SD)] with a mean follow-up of 26 +/- 14 months. Mean weight loss was 32 +/- 16 kg. Most weight reduction occurred within the first 6 months, followed by near-stabilisation or even slight weight regain. Most biological parameters were obtained before surgery and after at least 6 months of follow-up. The high prevalence and severity of metabolic disturbances associated with the insulin resistance syndrome (hyperglycaemia, hyperinsulinaemia, decreased HDL cholesterol, hypertriglyceridaemia, elevated fibrinogen levels and hyperuricaemia) before gastroplasty were significantly decreased after weight loss. No major biological deficiencies were observed following gastroplasty, except low iron serum levels. It is concluded that marked weight loss associated with gastroplasty involved a remarkable reduction in the prevalence and severity of several biological abnormalities classically considered as cardiovascular risk factors.
Disciplines :
Surgery
Author, co-author :
Luyckx, Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Desaive, Claude ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
Dewe, W.
Gielen, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie maxillo-faciale et plastique
Lefebvre, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity.
Sjöström L. Morbidity of severely obese subjects. Am J Clin Nutr, 1992, 55, 508S-515S.
Sjöström L. Mortality of severely obese subjects. Am J Clin Nutr, 1992, 55, 516S-523S.
Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease : A 26-year follow-up of participants in the Framingham Heart Study. Circulation, 1983, 67, 968-977.
Jung RT. Obesity as a disease. Br Med Bull, 1997, 53, 307-321.
Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Therapeutics, 1996, 18, 1006-1035.
Scheen AJ, Desaive C, Lefèbvre PJ. Therapy for obesity today and tomorrow. Baillière's Clin Endocrinol Metab, 1994, 8, 705-727.
Benotti P, Forse R. The role of gastric surgery in the multidisciplinary management of severe obesity. Am J Surg, 1995, 169, 361-366.
NIH Consensus Development Conference : Gastrointestinal surgery for severe obesity. Am J Clin Nutr, 1992, 55, 615S-619S.
Laws H. Standardized gastroplasty orifice. Am J Surg, 1981, 141, 393-394.
Kuzmak L. Gastric banding in surgery for the morbidly obese patient. In : Dietel M, ed. "Surgery for the morbidly obese patient", Chapter 12. Philadelphia : Lea and Febiger, 1989, 225-259.
Desaive C. A critical review of a personal series of 1000 gastroplasties. Int J Obesity, 1995, 19 (Suppl. 3), S61-S65.
SAS Institute Inc : SAS/STAT User's Guide, Version 6.11, Fourth edition. SAS Institute Inc. Cary, North Carolina, 1995.
Renquist KE, Cullen JJ, Barnes D, Tang S, Doherty C, Mason EE. The effect of follow-up on reporting success for obesity surgery. Obes Surg, 1995, 5, 285-292.
Kolanowski J. Surgical treatment for morbid obesity. Br Med Bull, 1997, 53, 433-445.
Scheen AJ, Paquot N, Letiexhe M, Paolisso G, Castillo MJ, Lefèbvre PJ. Glucose metabolism in obese subjects : lessons from OGTT, IVGTT, and clamp studies. Int J Obesity, 1995, 19 (Suppl. 3), S14-S20.
Van Gaal LF, Zhang A, Steijaert MM, De Leeuw IH. Human obesity : from lipid abnormalities to lipid oxidation. Int J Obesity, 1995, 19 (Suppl. 3), S21-S26.
Bonora E, Targher G, Zenere MB et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obesity, 1996, 20, 975-980.
Le Devehat C, Khodabandehlou T, Dougny M. Etudes des paramètres hémorhéologiques dans l'obésité isolée. Diabete Metab, 1992, 18, 43-47.
Valensi P, Paries J, Maheo P. Erythrocyte rheological changes in obese patients : influence of hypcrinsulinism. Int J Obesity, 1996, 20, 814-819.
Jarrett RJ. The cardiovascular risk associated with impaired glucose tolerance. Diab Med, 1996, 13, S15-S19.
Fontbonne A, Charles MA, Thibault N et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population : the Paris Prospective Population Study : 15-year follow-up. Diabetologia, 1991, 34, 356-361.
Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary heart disease (the PROCAM experience). Am J Cardiol, 1992, 70, 733-737.
Gordon DJ, Probstfeld JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease : four prospective American series. Circulation, 1989, 79, 8-15.
Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart disease risk : evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epid, 1995, 142, 288-294.
Ernst E. Fibrinogen : an independent risk factor for cardiovascular disease. BJM, 1991, 303, 596-597.
DeFronzo RA, Ferrannini E. Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and artherosclerotic cardiovascular disease. Diabetes Care, 1991, 14, 173-194.
Kolanowski J. Gastroplasty for morbid obesity : the internist's view. Int J Obesity, 995, 19 (Suppl. 3), S56-S60.
Toumiaire J, Fimbel S, Penet D et al. Traitement de l'obésité sévère par gastroplastie verticale calibrée : 55 observations. Presse Méd, 1995, 24, 259-262.
Leticxhc MR, Scheen AJ, Gérard PL, Desaive C, Lefèbvre PJ. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab, 1995, 80, 393-399.
Scheen AJ, Luyckx FH, Triches K, Letiexhe M, Desaive C, Lefèbvre PJ. Anomalies de la tolérance au glucose dans l'obésité sévère : réversibilité après amaigrissement induit par une gastroplastie. Rev Franç Endocrinol Clin, 1997, 38, 217-228.
Scheen AS. Aggressive weight reduction treatment in the management of type 2 diabetes. Diab Metab, 1998, 24, 116-123.
Datillo A, Kris-Etherton P. Effects of weight reduction on blood lipids and lipoproteins : a meta-analysis. Am J Clin Nutr, 1992, 56, 320-328.
Gleysteen JJ, Barboriak J, Sasse E. Sustained coronary-risk-factor reduction after gastric bypass for morbid obesity. Am J Clin Nutr, 1990, 51, 774-778.
Olsson S, Petersson B, Sörbris R, Nilsson-Ehle P. Effects of weight reduction after gastroplasty on glucose and lipid metabolism. Am J Clin Nutr, 1984, 40, 1273-1280.
Von Schenck, Wallentin L, Lennmarken C, Larsson J. Lipoprotein metabolism following gastroplasty in obese women. Scand J Clin Lab Invest, 1992, 52, 269-274.
Brolin R, Kenler H, Wilson A, Kuo P, Cody R. Serum lipids after gastric bypass surgery for morbid obesity. Int J Obesity, 1990, 14, 939-950.
Facchini F, Chen Y-DI, Hollenbeck CB. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA, 1991, 266, 3008-3011.
Ditschuneit H, Fleehtner-Mors M, Adler G. Fibrinogen in obesity before and after weight loss. Obes Res, 1995, 3, 43-48.
Luyckx FH, Desaive C, Thiry A et al. Liver abnormalities in severely obese subjects : effect of drastic weight loss after gastroplasty. Int J Obesity, 1998, 22, 222-226.
Sjöström L, Larsson B, Backman L et al. Swedish Obese Subjects (SOS). Recruitment for an intervention study and a selected description of the obese state. Int J Obesity, 1992, 16, 465-479.
Sjöström L. Nabro K, Sjöström D. Costs and benefits when treating obesity. Int J Obesity, 1995, 19 (Suppl. 6), S9-S12.
